Agios Pharmaceuticals
AGIO

$48.05

0.52%

Market Cap: 2.73B

About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Employees: 386

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 24

35% more capital invested

Capital invested by funds: $1.29B [Q4 2023] → $1.74B (+$451M) [Q1 2024]

9% more funds holding

Funds holding: 167 [Q4 2023] → 182 (+15) [Q1 2024]

2.41% more ownership

Funds ownership: 103.38% [Q4 2023] → 105.79% (+2.41%) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 56

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

20% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $15.5M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$30

38%

downside

Avg. target

$43

11%

downside

High target

$53

10%

upside

6 analyst ratings

2 positive

33%

4 neutral

67%

0 negative

0%

JP Morgan Tessa Romero	4%downside $46	Neutral Reinstated	13 Jun 2024
Goldman Sachs Salveen Richter	10%upside $53	Neutral Maintained	4 Jun 2024
RBC Capital Gregory Renza	10%upside $53	Outperform Maintained	4 Jun 2024
Goldman Sachs Salveen Richter	31%downside $33	Neutral Maintained	3 May 2024
JP Morgan Tessa Romero	38%downside $30	Neutral Maintained	23 Feb 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights.

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Zacks Investment Research

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itself for potential FDA approvals in 2025 and 2026. A $905 million upfront payment from Royalty Pharma is contingent on FDA approval of Vorasidenib by August 2024.

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Zacks Investment Research

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo –

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET.

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Zacks Investment Research

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Investors Business Daily

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock is poised to break out at the open.

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out

See News Rankings